What is NKTX's market cap?

$123.91M, based on the Nov 4 close of $1.73.

Does Nkarta pay a dividend?

No regular cash dividend has been paid in the last year.

How much of NKTX is sold short?

3.4M shares, 8.1% of float, as of Oct 15, 2026.

What sector is NKTX in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · NKTXHealthcarePharmaceuticals

Nkarta, Inc. Common Stock (NKTX)

$1.73+13.07%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$1.72▼ 17.15% in range

Nov 3, 2025Low $1.52 · High $3.67Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Nkarta closed at $1.73 on Nov 4, up 13.07%, 52.9% below its 52-week closing high. Volume of 1.9M shares was 1.63× its 20-day average (above normal).

Split-adjusted performance: -25.1% over one month, -47.9% over six months, -16.4% over one year.

Short interest was 3.4M shares at the Oct 15 settlement, down 6.5% from the prior report (8.1% of float, 4.9 days to cover).

Market cap$123.9M71.6M shares

Revenue · quarter$0.00—

Diluted EPS$-0.54—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range1.52 – 3.67−52.9% from high

Volume1.9M1.63× 20-day avg

Volatility · 60d65.9%Annualised

Short % of float8.1%4.9 days to cover

Net cash$182.8MCash $182.8M

Next earnings—Not scheduled

Split-adjusted performance

1W +0.6%1M −25.1%3M −24.5%6M −47.9%YTD −6.5%1Y −16.4%3Y −14.8%5Y −89.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum27

Revenue growth—

Net margin—

Value (low P/E)—

Size43

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short3.4M−6.5% vs prior

Days to cover4.9Settled Oct 15

% of float8.1%

Short vol. 10d45.6%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
NKTXNkarta	$1.73	+13.07%	−47.9%	—	—	—	$123.9M
FHTXFoghorn Therapeutics	$2.10	−1.41%	−55.1%	+112.7%	−44.7%	—	$124.7M	Compare
NERVMinerva Neurosciences	$2.57	+9.36%	−58.7%	—	—	—	$122.7M	Compare
YARWYarrow Bioscience	$14.91	−18.84%	—	—	—	—	$125.8M	Compare
DERMJourney Medical	$4.73	+1.94%	−9.2%	+18.9%	−1.7%	—	$133.5M	Compare
SPRBSpruce Biosciences	$46.61	+8.88%	−19.5%	—	—	—	$134.0M	Compare
ANIXAnixa Biosciences	$3.28	+7.37%	+7.2%	—	—	—	$114.0M	Compare
ORGOOrganogenesis Holdings	$0.8700	+4.19%	−66.0%	−56.7%	−227.0%	—	$111.9M	Compare
PYXSPyxis Oncology	$1.66	+1.22%	−27.8%	−100.0%	—	—	$138.5M	Compare

News about Nkarta

All news →

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026GlobeNewswire Inc. · Sep 8, 2026▲ Positive Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceGlobeNewswire Inc. · Jun 26, 2026▲ Positive Nkarta to Participate in March Investor ConferencesGlobeNewswire Inc. · Feb 27, 2026Neutral

Quick answers

What does Nkarta do?: Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable.
What is NKTX's market cap?: $123.91M, based on the Nov 4 close of $1.73.
Does Nkarta pay a dividend?: No regular cash dividend has been paid in the last year.
How much of NKTX is sold short?: 3.4M shares, 8.1% of float, as of Oct 15, 2026.
What sector is NKTX in?: Healthcare, in the Pharmaceuticals industry.

About Nkarta

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

HQ: South San Francisco, CA106 employeesListed Jul 10, 2020nkartatx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology